Results 41 to 50 of about 8,252,758 (233)

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

open access: yesAnnals of the Rheumatic Diseases, 2019
Background Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which ...
B. Hellmich   +25 more
semanticscholar   +1 more source

Pericarditis revealing large vessel vasculitis. [PDF]

open access: yes, 2011
Large vessels vasculitis and more specifically, Giant cell arteritis, is characterized by increased inflammatory markers, headaches and altered clinical status.
Soyfoo, Muhammad Shahnawaz   +5 more
core   +1 more source

Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis

open access: yesArthritis Research & Therapy, 2022
Objective To assess markers of neutrophil activation such as calprotectin and N-formyl methionine (fMET) in anti-neutrophil cytoplasmic autoantibody-associated vasculitis (AAV) and large-vessel vasculitis (LVV).
Despina Michailidou   +18 more
semanticscholar   +1 more source

The role of the host—Neutrophil biology

open access: yesPeriodontology 2000, EarlyView., 2023
Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple   +4 more
wiley   +1 more source

Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study

open access: yesRMD Open, 2022
Objective The aim was to identify any association between imaging signs of vessel wall inflammation (positron emission tomography–CT (PET-CT) score and CT/MR wall thickening) and synchronous and subsequent vascular damage (stenoses/dilations) in patients
G. Besutti   +14 more
semanticscholar   +1 more source

Segmental cutaneous leukocytoclastic vasculitis associated with herpes zoster: a case report and literature review

open access: yesDermatology Reports, 2023
Varicella zoster virus (VZV) infection may cause large or medium vessel vasculitis, including granulomatous arteritis of the nervous system and central nervous system vasculitis.
Keiko Furuoka   +5 more
doaj   +1 more source

Large-vessel vasculitis following the Pfizer-BioNTech COVID-19 vaccine

open access: yesInternal and Emergency Medicine, 2022
At the end of 2019, a novel coronavirus now known as severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in the Hubei Province of China.
M. Gilio, G. D. De Stefano
semanticscholar   +1 more source

Disease activity assessment in large vessel vasculitis

open access: yesReumatismo, 2011
Disease activity assessment in large vessel vasculitis (LVV) is often challenging for physicians. In this study, we compared the assessment of disease activity based on inflammatory markers, clinical indices (Indian Takayasu Activity Score [ITAS] and the
N. Pipitone   +11 more
doaj   +1 more source

The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis.

open access: yesReumatismo, 2022
OBJECTIVE Since of the last publication of last recommendations on primary large-vessel vasculitis (LVV) endorsed by the Italian Society of Rheumatology (SIR) in 2012, new evidence emerged regarding the diagnosis and the treatment with conventional and ...
N. Ughi   +18 more
semanticscholar   +1 more source

Immune checkpoint inhibitor induced large vessel vasculitis

open access: yes, 2020
This is a case report of a 67-year-old patient with castration resistant metastatic prostate cancer who developed an immune-mediated large vessel vasculitis following treatment with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1).
Eslamian, Gelareh   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy